BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31619462)

  • 1. Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
    Okonska A; Bühler S; Rao V; Ronner M; Blijlevens M; van der Meulen-Muileman IH; de Menezes RX; Wipplinger M; Oehl K; Smit EF; Weder W; Stahel RA; Penengo L; van Beusechem VW; Felley-Bosco E
    Mol Cancer Ther; 2020 Feb; 19(2):552-563. PubMed ID: 31619462
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Guazzelli A; Meysami P; Bakker E; Demonacos C; Giordano A; Krstic-Demonacos M; Mutti L
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
    Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in
    Oehl K; Vrugt B; Wagner U; Kirschner MB; Meerang M; Weder W; Felley-Bosco E; Wollscheid B; Bankov K; Demes MC; Opitz I; Wild PJ
    Clin Cancer Res; 2021 Apr; 27(8):2277-2291. PubMed ID: 33547197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
    Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
    [No Abstract]   [Full Text] [Related]  

  • 6. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
    Parrotta R; Okonska A; Ronner M; Weder W; Stahel R; Penengo L; Felley-Bosco E
    J Thorac Oncol; 2017 Aug; 12(8):1309-1319. PubMed ID: 28389374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
    Sacco JJ; Kenyani J; Butt Z; Carter R; Chew HY; Cheeseman LP; Darling S; Denny M; Urbé S; Clague MJ; Coulson JM
    Oncotarget; 2015 May; 6(15):13757-71. PubMed ID: 25970771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
    Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
    Tian L; Chen C; Guo Y; Zhang F; Mi J; Feng Q; Lin S; Xi N; Tian J; Yu L; Chen Y; Cao M; Lai C; Fan J; Zhang Y; Chen G
    Neoplasia; 2021 Jul; 23(7):643-652. PubMed ID: 34126361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
    Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
    Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BAP1: a new paradigm for mesothelioma.
    Schunselaar LM; Zwart W; Baas P
    Lung Cancer; 2017 Jul; 109():145-146. PubMed ID: 28342657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAP1 protein is a progression factor in malignant pleural mesothelioma.
    Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
    Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification.
    Barnett SE; Kenyani J; Tripari M; Butt Z; Grosman R; Querques F; Shaw L; Silva LC; Goate Z; Marciniak SJ; Rassl DM; Jackson R; Lian LY; Szlosarek PW; Sacco JJ; Coulson JM
    Mol Cancer Res; 2023 May; 21(5):411-427. PubMed ID: 36669126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma.
    Parasramka M; Yan IK; Wang X; Nguyen P; Matsuda A; Maji S; Foye C; Asmann Y; Patel T
    Mol Cancer; 2017 Jan; 16(1):22. PubMed ID: 28122578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
    Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
    Chen P; Wu JN; Shu Y; Jiang HG; Zhao XH; Qian H; Chen K; Lan T; Chen CG; Li J
    Clin Sci (Lond); 2018 Jul; 132(13):1417-1433. PubMed ID: 29853661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.
    Hakiri S; Osada H; Ishiguro F; Murakami H; Murakami-Tonami Y; Yokoi K; Sekido Y
    Cancer Sci; 2015 Aug; 106(8):990-9. PubMed ID: 26011428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BAP1 mutations predispose to malignant mesothelioma.
    Testa JR; Cheung M; Pei J; Below JE; Tan Y; Sementino E; Cox NJ; Dogan AU; Pass HI; Trusa S; Hesdorffer M; Nasu M; Powers A; Rivera Z; Comertpay S; Tanji M; Gaudino G; Yang H; Carbone M
    Nat Genet; 2011 Aug; 43(10):1022-5. PubMed ID: 21874000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.